公开(公告)号：US20200268879A1

公开(公告)日：2020-08-27

申请号：US16795953

申请日：2020-02-20

申请人： WAYNE STATE UNIVERSITY

发明人： Haipeng Liu ,  Chunsong Yu

IPC分类号： A61K39/39 ,  A61K47/54 ,  C12N15/117

摘要： Amphiphilic oligonucleotide conjugates that enhance adjuvant function are disclosed. The conjugates typically include: a lipophilic component, and conjugated thereto (directly or indirectly) an immunomodulating oligonucleotide that, if it were not conjugated to the lipophilic component, would suppress TLR7 and/or TLR8 stimulation. In the presence of albumin, these conjugates significantly enhance adjuvant function, in particular the function of TLR7/8-mediated adjuvants such as an imidazoquinolinamine. The conjugates can be administered, along with an adjuvant compound, to a subject in order to cause and/or enhance an immune response (for instance, to an infectious agent or a cancer antigen) in the subject.

公开(公告)号：US10478482B2

公开(公告)日：2019-11-19

申请号：US16285353

申请日：2019-02-26

申请人： Markus Maeurer

发明人： Markus Maeurer

IPC分类号： A61K39/04 ,  A61K39/00 ,  C07K14/35 ,  C12Q1/48 ,  G01N33/569 ,  C12N15/117

摘要： The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.

公开(公告)号：US20190328769A1

公开(公告)日：2019-10-31

申请号：US16473535

申请日：2017-12-27

申请人： THE UNIVERSITY OF TOKYO ,  KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION

发明人： Satoshi UCHIDA ,  Keiji ITAKA ,  Kazunori KATAOKA ,  Naoto YOSHINAGA

IPC分类号： A61K31/7115 ,  C12N15/117 ,  A61K47/69 ,  A61K39/00

摘要： The present invention provides a functionalized mRNA including mRNA and double-stranded RNA including at least one RNA oligomer hybridized with mRNA. Functionalized mRNA is provided according to this configuration.

公开(公告)号：US10428331B2

公开(公告)日：2019-10-01

申请号：US15107536

申请日：2015-01-14

申请人： MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

发明人： Ann-Marie Broome ,  Suraj Dixit ,  Satish Nadig ,  Carl Atkinson

IPC分类号： A61K39/395 ,  C12N15/117 ,  A61K31/365 ,  A61K31/436 ,  A61K31/713 ,  A61K35/17 ,  A61K38/13 ,  A61K38/17 ,  A61K38/20 ,  C12N15/11 ,  A61K31/395 ,  A61K47/62 ,  A61K47/69 ,  A61K35/12

摘要： Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

公开(公告)号：US20190194282A1

公开(公告)日：2019-06-27

申请号：US16329577

申请日：2016-12-15

申请人： TARGIMMUNE THERAPEUTICS AG

发明人： Alexander LEVITZKI ,  Yael LANGUT

IPC分类号： C07K14/47 ,  A61P35/00 ,  C07K16/30 ,  C12N15/62 ,  C12N15/117

CPC分类号： C07K16/3069 ,  A61K38/00 ,  A61P35/00 ,  C07K14/4748 ,  C07K2317/622 ,  C07K2317/77 ,  C07K2319/60 ,  C07K2319/85 ,  C12N15/117 ,  C12N15/62 ,  C12N2310/17 ,  C12N2320/32

摘要： Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.

公开(公告)号：US20190177731A1

公开(公告)日：2019-06-13

申请号：US16308420

申请日：2017-06-08

申请人： Presicent and Fellows Harvard College

发明人： Ying Kai Chan ,  George M. Church

IPC分类号： C12N15/117 ,  C12N7/00 ,  A61P29/00

摘要： Modified viral genomes are able to reduce induction of inflammatory and immune anti-viral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.

公开(公告)号：US20190175715A1

公开(公告)日：2019-06-13

申请号：US16285353

申请日：2019-02-26

申请人： Markus Maeurer

发明人： Markus Maeurer

IPC分类号： A61K39/04 ,  C12Q1/48 ,  C12N15/117 ,  C07K14/35

CPC分类号： A61K39/04 ,  A61K2039/522 ,  C07K14/35 ,  C12N15/117 ,  C12Q1/48

摘要： The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.

公开(公告)号：US10278991B2

公开(公告)日：2019-05-07

申请号：US15310735

申请日：2015-05-14

申请人： TARGIMMUNE THERAPEUTICS AG

发明人： Alex Levitzki ,  Salim Joubran ,  Alexei Shir ,  Maya Zigler ,  Alaa Talhami ,  Yael Langut

IPC分类号： A61K47/34 ,  A61K35/14 ,  A61K45/06 ,  C12N15/117 ,  A61K47/60 ,  A61K47/59 ,  A61K35/17

摘要： A polyplex of a double stranded RNA and a polymeric conjugate is provided, wherein the polymeric conjugate consists of a linear polyethyleneimine covalently linked to one or more polyethylene glycol (PEG) moieties, each PEG moiety being conjugated via a linker to a targeting moiety capable of binding to a cancer antigen.

公开(公告)号：US20190117798A1

公开(公告)日：2019-04-25

申请号：US16229509

申请日：2018-12-21

申请人： ModernaTX, Inc.

发明人： Gilles Besin ,  Stephen Hoge ,  Joseph Senn ,  Kerry Benenato ,  Staci Sabnis

IPC分类号： A61K48/00 ,  C12N15/88 ,  A61K47/10 ,  A61K47/54 ,  A61K31/7115 ,  A61K9/127 ,  A61K47/69 ,  A61K47/60 ,  A61K39/39 ,  C08G65/332 ,  C08G65/333 ,  C08G65/334 ,  C08G65/335 ,  C12N15/117 ,  A61K31/713

摘要： This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

公开(公告)号：US10238682B2

公开(公告)日：2019-03-26

申请号：US14936375

申请日：2015-11-09

申请人： Rheinische Friedrich-Wilhelms-Universität Bonn

发明人： Gunther Hartmann ,  Veit Hornung

IPC分类号： A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  A61K31/7115 ,  A61K31/7105 ,  C07H21/00 ,  A61K45/06 ,  C12N15/117

摘要： Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1β production. Bacterial RNA also induces type I IFN production. 5′ phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5′ triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1β production, in a target cell-specific manner.